Biogen (BIIB) Could Be 5% Undervalued After 52 Week Lupus Data

Biogen (BIIB) is back in focus after releasing 52 week Phase 2 data for litifilimab in cutaneous lupus erythematosus, reporting sustained improvements in skin activity and a safety profile described as consistent with earlier studies. For investors, the litifilimab update comes after a solid run in the Biogen share price, with a 90 day share price return of 17.6% and a year-to-date share price gain of 26.9%. The 1 year total shareholder return of 56.0% contrasts with declines over the 3 and 5...